Johnson & Johnson succeeds in late-stage multiple myeloma trial

[Cancer In The Blood]
wildpixel

* Johnson & Johnson (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) has announced that its late-stage trial for Tecvayli (teclistamab), used in combination with Darzalex Faspro, achieved its main goal in treating relapsed or refractory multiple myeloma.
* This combination was compared to the investigator's choice of either Darzalex Faspro with pomalidomide and dexamethasone or Darzalex Faspro with bortezomib and dexamethasone.
* Additionally, the secondary endpoint concerning overall survival showed statistically significant results during the first interim analysis.
* The company said [https://seekingalpha.com/pr/20268660-tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free]that the safety profile of the treatment combination was consistent with the known safety profiles of each monotherapy.

MORE ON JOHNSON & JOHNSON

* Johnson & Johnson 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4829876-johnson-and-johnson-2025-q3-results-earnings-call-presentation]
* Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4829833-johnson-and-johnson-jnj-q3-2025-earnings-call-transcript]
* Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again [https://seekingalpha.com/article/4829768-johnson-and-johnson-q3-earnings-surprise-icotrokinra-shines-again]
* J&J hit with first U.K. lawsuits over talc-related cancer claims [https://seekingalpha.com/news/4504695-jj-sued-uk-over-talc-related-cancer-claims]
* Johnson & Johnson outlines orthopaedics spin-off and targets 5.7% reported sales growth for 2025 amid accelerating MedTech and Innovative Medicine momentum [https://seekingalpha.com/news/4503999-johnson-and-johnson-outlines-orthopaedics-spin-off-and-targets-5_7-percent-reported-sales]